This list is based on the watchlists of people on Stock Events who follow DTC.MU. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Show more...
FAQ
What is Defence Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Defence Therapeutics stocks are traded under the ticker DTC.MU.
In which sector is Defence Therapeutics located?▼
Defence Therapeutics operates in the Health & Wellness sector.
When did Defence Therapeutics complete a stock split?▼
Defence Therapeutics has not had any recent stock splits.
Where is Defence Therapeutics headquartered?▼
Defence Therapeutics is headquartered in Montreal, United States.